CTTH CTT PHARMACEUTICAL HOLDINGS, INC.

Executive Summary

CTT Pharmaceutical Holdings, Inc. filed Amendment No. 2 to its S-1 registration statement, registering 6,250,000 shares for resale by RH2 Equity Partners under an Equity Line of Credit (ELOC) agreement. The ELOC provides up to $10 million in potential funding, but the company is a development-stage pharmaceutical firm with no current revenue, a history of losses, and a going-concern qualification from its auditors. The stock trades on the OTCQB at $0.0825 per share, and the filing updates the ELOC terms from the prior S-1 filed in December 2025.

Actionable Insight

Key Facts

• Registers 6,250,000 shares for resale by RH2 Equity Partners under an ELOC dated September 19, 2025.
• ELOC provides up to $10 million in potential funding, but the company may only receive proceeds if it sells shares to RH2.
• Company is a development-stage pharmaceutical firm with no revenue in the past two years; net loss of $155,907 in FY2025.
• Auditors include a 'going concern' qualification in the financial statements.
• Cash balance as of March 31, 2026 was only $7,089.
• Stock price on May 26, 2026 was $0.0825 per share; at that price, selling all 6.25M registered shares would yield only ~$876,236 in gross proceeds.
• Management states it plans to use no more than $1 million from the ELOC unless the stock price exceeds $1 per share.
• Company has a history of losses and minimal operations; its primary assets are patents expiring between 2028 and 2038.
• Officers and directors collectively own approximately 51.1% of outstanding shares.

Financial Impact

Potential gross proceeds of up to $10 million from ELOC, but at current stock price of $0.0825, selling all 6.25M registered shares would yield only ~$876,236. Company had only $7,089 cash as of March 31, 2026.

Risk Factors

• Going-concern risk: company has minimal cash and no revenue.
• Extreme dilution risk: at current stock price, raising even $1 million would require issuing ~12 million shares (20%+ dilution).
• Regulatory risk: nicotine strips require FDA approval, which is uncertain and costly.
• Penny stock status limits institutional interest and liquidity.
• Management controls ~51% of shares, limiting minority shareholder influence.

Market Snapshot

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

US Market Status